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Abstract
Background: Co-infection of  HBV with HIV is associated with significant morbidity and mortality globally. In spite of  increas-
ing reports of  HIV/HBV co-morbidities in Nigeria, little or no data exists on this subject in Anyigba. Therefore,we determined 
the prevalence of  hepatitis B surface antigenemia among HIV positive patients on anti-retroviral treatment programme in Any-
igba, Kogi State, North-Central Nigeria.
Methods: Sera samples obtained from 200 consented HIV patients were screened for HBsAg using the commercial rapid test 
membrane-based qualitative immunoassay. A structured questionnaire was used to collect information on patients’ demographic 
variables and probable risk factors for HBV transmission. 
Results: Overall, 3.5% of  HIV patients were seropositive to HBsAg and the difference between seroprevalence rates and 
patients’ age as well as gender was not statistically significant (p>0.05). There was significant difference between patients’ de-
mographic variables such as marital status (p=0.013) and educational level (p=0.004) and HBsAg seropositivity. Patients with a 
history of  surgical applications (p=0.01) and who indulged in alcoholism (p=0.03) significantly had higher rates of  concomitant 
HIV/HBV infection in the study area.
Conclusion: Our findings underscore the importance of  routine screening for HBV in the HIV infected populations especially 
in developing countries where the infection is endemic. We advocate for public enlightenment programmes on routes of  virus 
acquisitions with a view to reduce the morbidity and mortality associated HIV/HBV co-infection.
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Hepatitis B virus (HBV) is the most prevalent etiology 
of  viral inflammation of  the human liver1. Globally, more 
than 2 billion people are infected with Hepatitis B vi-
rus2,3, with approximately 360 million people being HBV 
carriers4. sub-Saharan Africa alone has over 8% of  the 
HBV carriers rate5,6. Nigeria is one of  the countries in 
sub-Saharan Africa with high burden of  HBV infection7. 
World Health Organization in8 defines low prevalence 
as <2%, moderate prevalence as 2-8% and high preva-
lence as >8% HBsAg positivity. Approximately 13.6% 
of  the total Nigerian populations are chronic carriers of  
HBV7. The risk of  contracting HBV in Nigeria, a coun-
try with approximately 20,000 HBsAg seropositivity rate, 
is wide-ranging and reasons have been attributed to low 
compliance with HBV vaccination and high exposure 
through unprotected sexual intercourse, blood transfu-
sion and perinatal transmission9.  
 
Hepatitis B virus is a highly infectious agent that causes 
both acute and chronic infections across the globe10 with 
prolonged forms often incriminated in liver cirrhosis 
and hepatocellular carcinoma11 and about 600,000 deaths 
annually12.  HBV is 50 - 100 times more infectious than 
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HIV and 10 times more infectious than hepatitis C virus 
(HCV)13. Common practices such as use of  tooth brush 
or razor blade can easily predisposed one to HBV infec-
tion due to the low infectious dose of  the virus13.  Ma-
jority of  childhood infection results in chronic carriers 
of  the virus while infection in adolescents/adults which 
usually occurs via sexual contact, contaminated needles, 
and less often from transfusion of  blood products, usual-
ly resolves unless the individual is immunocompromised 
(e.g. HIV/AIDS patients)14. Patients with chronic disease 
usually do not present with symptoms; however, cirrhosis 
and liver cancer may eventually develop15. 
 
HBV coinfection is one of  the frequent complications in 
HIV positive patients16 and due to the shared routes of  
transmission; the incidence rate of  coinfection with both 
viruses is on the increase17. HIV/HBV co-morbidity has 
been identified as the one of  the major factors that accel-
erates the progression of  HIV disease18 and individuals 
coinfected with both viruses have been shown to be 17 
times more likely at risk for death from complications of  
liver disease than those monoinfected with HBV19. Previ-
ous studies has documented HBV protein X that enhanc-
es the replication of  HIV-120 while HIV decreases the 
rate of  HBsAg clearance in acute infection and enhanc-
es the progression of  liver disease in those with chronic 
hepatitis B21. With the introduction of  HAART in both 
industrialized and developing countries, the incidence of  
AIDS-related opportunistic infections have decreased 
while liver disease resulting from chronic infection with 
HBV and HCV has emerged leading causes of  morbid-
ity and mortality in HIV-infected patients22-25. This is as 
a result of  decreased response to HBV treatment which 
in turn raises the risk of  hepatotoxicity of  HAART and 
drug interactions26. The interaction of  HBV and HIV 
therapies can lead to additional complexities due to in-
crease potential for the selection of  drug- resistant mu-
tations26.
Epidemiological studies have shown that the seropreva-
lence of  HBV/HIV co-infection vary from 5 to 10% in 
the USA to 20-30% in parts of  sub-Saharan Africa and 
Asia12. In Nigeria, HIV/HBV co-infection rate is esti-
mated to be within 10% and 70%26. Study on HIV/HBV 
co-infection is important as it will help to compliment the 
epidemiological data on the two viruses in Nigeria which 
in turn would provide information on the variation in the 
prevalence of  HIV/HBV co-infection rate6.
In Anyigba, Kogi State, Nigeria, there is currently no 
documented report on HBV/HIV co-infection to the 
best of  our knowledge. In light of  this background, it be-
comes crucial to determine the prevalence of  HBV/HIV 
in Anyigba which will complement the epidemiological 
data on the two viruses in Nigeria and will in turn influ-
ence policy making as well as prevention and treatment 
strategies for HBV/HIV co-infection particularly in view 




This study was conducted in Anyigba, a city in Kogi State, 
found in the North Central region of  Nigeria. Anyigba 
which lies between latitude 7015’-7029’ north and lon-
gitude 7011’-7032’ east, has an average altitude of  420m 
above sea level27. Behavioral practices such as early age 
at first sexual intercourse, use of  unscreened blood and 
blood products, scarification marks, promiscuity and in-
travenous drug use are common among the inhabitants.
Study population
This was a hospital-based cross-sectional study in which 
200 consenting HIV positive patients on Highly Active 
Anti-retroviral Therapy (HAART) at the Grimard Hos-
pital and Maria Goretti Hospital between January and 
April, 2017 were recruited using a non-probability con-
venient sampling technique.  These hospitals run a week-
ly HIV/AIDS clinic and are the most utilized health fa-
cilities in the study area with a record of  approximately 
2000 HIV patients per year. Trained medical personnel in 
each hospital clearly explained the objectives/benefits of  
the study to the patients and only those who gave con-
sent by completing and endorsing filled-in questionnaires 
were consecutively recruited. Consenting attendees, male 
or female, aged 5 years and above who provided written 
informed consent were eligible for participation in the 
study. Ethical approval for the study was obtained from 
the hospital management board on health issues in accor-
dance with the code of  conduct for biomedical research 
involving human subjects (Ethical clearance no:058).
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Sample collection and storage
Two (2) ml of  blood sample was aseptically collected 
from each of  the 200 consenting HIV positive patients by 
vein-puncture into a well labeled non-anticoagulant tube. 
Information concerning patients’ demographic profile 
and associated risk factors were also obtained by means 
of  structured questionnaires. Blood sample obtained 
from each patient was centrifuged at 3000rpm for 8-10 
seconds to separate sera from whole blood. Sera samples 
were stored at -200C in line with the manufacturer’s in-
struction until screened for HBsAg. 
 
Assays for HBsAg
A one step test was carried out to detect HBsAg in serum 
using Coschesic strips®. This method is immuno-chro-
matographic and qualitative in nature and detects HBV 
antigen in human blood. The test strip which is coated 
with the mouse monoclonal anti-HBs capture antibody 
has more than 99.9% sensitivity and 98.6% specificity 
when read in-vitro. The test and interpretation of  the re-
sults were done in accordance with the guidelines of  the 
kit’s manufacturers.
Data analysis 
Sample size (N) was determined using formula N = 
Zα2pq /d2 where: Zα = standard normal deviate set at 
1.96, corresponding to 95% confidence level; p = prev-
alence, q=1-p and d = degree of  precision set at 0.05 
(95% confidence interval). Assuming a prevalence of  
14% based on the most recent HBsAg prevalence from 
a similar study28, q=86% (0.86) and N =185 which was 
approximated to the nearest hundred as 200. Data gen-
erated from the study was analyzed using the statistical 
packages for social sciences (SPSS version 16.0). Descrip-
tive data was presented as simple summaries in statistical 
tables. Chi square test was used to establish differences 
between participants’ variables and prevalence rates. A 
p-value 0.05 was set as level of  statistical significance.
Results
Table 1 shows the socio-demographic data and outcome 
of  HBsAg test among HIV patients in Anyigba. Seven 
(3.5%) of  the 200 HIV patients in this study tested pos-
itive to HBsAg with the highest prevalence rate (13.3%) 
in patients that were aged ≥ 51. Sixty one males and 139 
females participated in this study, out of  which 2(3.27%) 
males and 5(3.59%) females respectively were positive 
to HBsAg. Though the number of  participated females 
were twice that of  the males, the difference between gen-
der and HBV infection was not statistically significant 
(p>0.05).  Marital status related seroprevalence showed 
higher HBV prevalence (20%) among HIV patients 
who were widowed compared to those who were single 
(9.09%) and married (1.39%) and the difference between 
HBV infection and marital status was statistically signif-
icant (p<0.05). Educationally, patients with primary and 
no formal education had significantly higher hepatitis B 
surface antigenemia rate (37.0%) compared to those with 
secondary (4.2%) and tertiary (1.2%) levels of  education. 
Table 2 depicts the possible predisposing factors of  HBV 
infection. History of  surgery and high rate of  alcohol 
consumption were significantly related to HBV infection 
(p<0.05). Other factors such as poor knowledge of  HBV 
infection, history of  intravenous drug use, multiple sex-
ual partners, mouth-to-mouth kissing, history of  blood 
transfusion were also noted with higher HBsAg seroprev-
alence rates although, the difference between each vari-
able and HBsAg seropositivity was not statistically signif-
icant (p>0.05).
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Table 1: HBV infection distribution in relation to socio-demographic 
characteristics of HIV patients 
___________________________________________________________ 
Variable                             No tested             No (%) positive                  P-value 
_________________________________________________________________ 
Age range            
5-20                                            25                          1(4.0) 
21-30                                          66                       2(3.0) 
31-40                                          42                       1(12.4)           0.30 
41-50                                          52                       1(1.9) 
15                   15                   2(13.3) 
  
Gender 
Male                         61                         2(3.27)  
Female                       139                        5(3.59)                                0.91 
  
Marital status 
Single           36                          3(9.09)   
Married                      146                         2(1.39)                        0.013 
Divorced           6                            0(0.00)   
Widowed           12                         2(20.00)    
  
Highest qualification 
None                                         4                            1(25.0) 
Primary                               25                        3(12.0)   
Secondary         24                        1(4.2)                                0.005 
Tertiary       147                        2(1.2)    
  
Occupation 
Business woman       12             1(8.33)   
Students        34                        2(5.88)   
House wives        67                        2(2.99)                             0.85 
Civil servants        76                        2(2.63)   
Farmers          5                        0(0.00)   
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Discussion 
In HBV endemic countries, the severity of  HBV infec-
tion has been classified into low (<2%), moderate (2-
8%) and high (>8%) prevalence by WHO8. An overall 
3.5% HBsAg seropositivity was observed in this study, 
thus suggesting a moderate prevalence of  HBV infection 
among HIV patients undergoing anti-retroviral therapy 
in Anyigba, Kogi State, Nigeria. HBsAg seropositivity 
rate of  3.5% in the population of  HIV patients in this 
region calls for great concern as HBV/HIV co-morbid-
ity have been linked with high risk of  mother–to-child 
transmission and accelerated progression of  HIV infec-
tion20-21. Findings in this study is comparable to the 3.6% 
reported29 in Biu, Borno State, Nigeria. It is also similar 
to the 3.6% by Smit et al.30, 3.2% by Rai et al.31, 3% by 
Lodenyo et al.32 and 3.7% by de Almeida et al.33 previous-
ly reported among HIV patients in Netherlands, Japan, 
Johannesburg and Brazil respectively. Lower prevalence 
of  2.7%, 1.2%, 1.13%, 1.8%, and 2.6%was earlier report-
ed among HIV positive patients in Nigeria, Tanzania, 
Mali, Iran and New York respectively34-38. Okonko et al.39 
also reported 2.5% HBV/HIV coinfection among appar-
ently healthy blood donors in Ibadan, Nigeria. The sero-
prevalence rate in our study is however lower than the 
prevalence of  HBV/HIV co-infection range of  10-70 % 
earlier reported for Nigeria26.  This lower prevalence rate 
is likely due to the efforts of  the public health agencies 
on HIV/AIDS prevention in the Country since measures 
aimed at preventing HIV infection also protect against 
HBV which shares similar transmission routes with HIV.
This study revealed that though more females (3.59%) 
than the males (3.27%) were seropositive, they were com-
parable (p = 0.91) in HBsAg seropositivity. This finding 
supports the report of  Sule et al.40 from the same setting 
Table 2: Distribution of HBsAg in positive sera in relation to 
            predisposing factors of HBV infection 
__________________________________________________________ 
Variable                                    No. tested         No Positive                 P-value 
______________________________________________________ 
1. Knowledge of HBV       
Yes                                                  73                   1(1.37)       0.21 
No                                                 127                  6(4.72)        
2. Mouth-To-Mouth Kissing 
Yes                                          142                 5(3.52)                      0.98 
No                                   58                 2(3.44)         
3. Shared Sharp Objects 
Yes                                  125                  3(2.40)                      0.52 
No                            75                   4(5.33)   
4. History of Circumcision 
Yes                                    61                  2(3.28)                       0.91 
No                            139                 5(3.60)   
5. No of Sexual Partners  
One                                                  25                   1(4.00)    
Two                                    55                  1(1.82)                      0.73 
 Two                                        120                              5 (4.17)   
6. History of STDs 
Yes                                            73    2(2.74)       0.66 
No                            127                  5(3.94)   
7. Use of Condom 
Regular                                            52                   3(5.77)   
Occasional                                       76                  2(2.63)      0.91 
Never                                            72                   2(2.78)   
8. Had Blood Transfusion 
Yes                             28                   1(3.57)     0.98 
No                           172                   6(3.49)   
9. History of Surgery 
Yes                                            25    3(12.00)                  0.01 
No                           175                    4(2.29)  
10. History of IDU 
Yes                                            7                    1(14.29)                  0.11 
No                           193                    6(3.11) 
11. Immunized For HBV 
Yes                                            68     3(4.41)   0.62  
No                           132                    4(3.03)  
12. Tribal Marks 
Yes                                           33      1(3.03)                 0.87 
No                           167                     6(3.59)                                
13. Alcohol Consumption Rate  
Low                                          162                     3(1.85)   
Moderate                                       31                     3(9.68)                  0.03 
High                                            7                     1(14.29)   
__________________________________________________________ 
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that both male and female were apparently equal in expo-
sure to HBV.  Previous studies41-44 reported similar find-
ings. The higher ratio of  females to male (2.3:1) in this 
study may be attributed to the fact that more females than 
males’ visits hospitals for medical attention in Nigeria, a 
reason previously reported45.
The significantly higher HBsAg seropositivity rate in HIV 
patients who were aged ≥50 was also reported46 among 
cohort of  HIV patients in Nassarawa State, Nigeria. Rea-
son for the age of  peak infection in this study could be 
attributed to increased parenthood responsibility as pa-
tients within this age group constitute economically pro-
ductive years in the Nigerian workforce. Unsafe sexual 
behavior of  the polygamous men coupled with their re-
ligious inclination, socio-economic, cultural and occupa-
tion of  the men as was previously opined by Bello et al.,29 
in the northern Nigeria could be possible explanation for 
the observed  prevalence. 
Analysis by marital status showed that the widowed pa-
tients significantly had higher HBsAg prevalence and 
reason could be attributed to absence of  family cover 
which could shield or restrain them from having multi-
ple sexual partners. This significant association of  marital 
status with HBV infection is in conformity with previ-
ous reports of  Sule et al.28  in Kogi State, Sirisena et al.47 
in Plateau State, Ezegbudo et al.48 in Anambra State and 
Mohammed et al.49 in Kanu State.
 
Educational related HBsAg seroprevalence revealed 
higher HBV infection in HIV patients with primary/
no formal education compared to those with secondary 
and tertiary levels of  education and there was a signifi-
cant difference between patient’s educational status and 
HBsAg seropositivity (p<0.05). The steady decrease in 
prevalence observed in present study may be a reflection 
of  the fact that educated individuals are likely more en-
lightened on the dangers posed by hepatitis B when sero-
positive to HIV and as such could implement strategies 
in preventing HBV infection. This may be evident from 
the lower prevalence of  HBsAg (1.37%) in patients with 
prior knowledge of  HBV infection compared to those 
without previous knowledge (4.72%).  This finding sup-
ports the assertion48 that prevalence rates of  infections 
such as HIV, HBV and HIV/HBV co-infection were in-
versely associated with educational status. Finding from 
present study was also previously corroborated by re-
ports of  Sule et al.28 in Ankpa and Mehmet et al.50 in the 
Southeastern region of  Turkey. Efforts geared towards 
improving the level of  education to reduce poverty and 
improve the quality of  life of  these vulnerable communi-
ties should therefore be considered in order to achieve a 
breakthrough in the fight against HIV/HBV co-morbid-
ity in Nigeria.
 
The significantly higher hepatitis B surface antigene-
mia rate in patients with history of  surgical application 
is similar with previous reports in Ethiopia51 and Benue 
State34, Nigeria. Practices such as use of  poorly unsteril-
ized instruments during surgical procedures as previously 
opined by Uwaezuoke et al.52 could be responsible for 
the significantly higher antigenemia among patients with 
such history. The strong association between alcohol 
consumption and HBV infection (P=0.00) in this study 
is in conformity with previous report of  Ndako et al.53, 
but contradicts finding of  Mbaawuaga et al.34 People who 
consume high rate of  alcohol are likely more promiscu-
ous and the fact that they may also fail to protect them-
selves through correct and consistent condom use could 
be a possible explanation for the higher predisposition to 
concomitants HIV/HBV infection. 
Limitations
The seroprevalence in the current study may reflect the 
true burden of  disease in the study area, since only hos-
pital-based cases were considered. Also, findings from 
the present study might not be generalizable to the entire 
country, as it showed to be at variance with some pub-
lished studies from other parts of  Nigeria. Despite these 
limitations, this study provides baseline seroprevalence 
data on HBV/HIV co-morbidity for future studies. 
Conclusion
The results of  this study showed that HBV/HIV co-in-
fection is endemic amongst HIV positive patients in 
Anyigba, Kogi State, North Central Nigeria. Considering 
the impart of  antiretroviral on the progression of  HBV, 
we recommend that all recently diagnosed HIV cases be 
screened for HBV as this will improve management of  
HBV/HIV co-infection. The high prevalence of  HBV 
infection in patients with no knowledge of  HBV infec-
tion underscores the need for continuous public health 
education on ways of  avoiding risky behaviors such as 
alcoholism and unprotected sexual intercourse. 
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